The role of the bisphenol A in diabetes and obesity The estrogenic endocrine disrupting chemical bisphenol A (BPA) and obesity The association between bisphenol A exposure and obesity in children—a systematic review with meta-analysis Urinary bisphenol A and obesity: NHANES 2003–2006 Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents Urinary bisphenol A (BPA) concentration associates with obesity and insulin resistance Association of bisphenol A and its substitutes, bisphenol F and bisphenol S, with obesity in United States children and adolescents Urinary bisphenol A and obesity in US children Urine bisphenol-A level in relation to obesity and overweight in school-age children Urinary bisphenol A levels and measures of obesity: results from the national health and nutrition examination survey 2003–2008 bisphenol A and indicators of obesity, glucose metabolism/type 2 diabetes and cardiovascular disease: a systematic review of epidemiologic research bisphenol A and the risk of obesity a systematic review with meta-analysis of the epidemiological evidence The influence of phthalates and bisphenol A on the obesity development and glucose metabolism disorders Association of exposure to bisphenol A with obesity and cardiometabolic risk factors in children and adolescents bisphenol A substitutes and obesity in US adults: analysis of a population-based, cross-sectional study bisphenol A exposure and associations with obesity among adults: a critical review bisphenol A, obesity, and type 2 diabetes mellitus: genuine concern or unnecessary preoccupation? Association of early life exposure to bisphenol A with obesity and cardiometabolic traits in childhood Systematic review and meta-analysis of early-life exposure to bisphenol A and obesity-related outcomes in rodents Urinary bisphenol A is associated with insulin resistance and obesity in reproductive‐aged women Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population The effect of environmental bisphenol A exposure on breast cancer associated with obesity Fat from plastics? Linking bisphenol A exposure and obesity Relationship between endocrine disruptors and obesity with a focus on bisphenol A: a narrative review Urinary bisphenol A and obesity in adults: results from the Canadian Health Measures Survey Exposure to bisphenol A, bisphenol F, and bisphenol S can result in obesity in human body Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity Urinary bisphenol A concentrations and the risk of obesity in Korean adults Associations of urinary concentrations of phthalate metabolites, bisphenol A, and parabens with obesity and diabetes mellitus in a Korean adult population … Changed preference for sweet taste in adulthood induced by perinatal exposure to bisphenol A—a probable link to overweight and obesity Resveratrol butyrate esters inhibit obesity caused by perinatal exposure to bisphenol A in female offspring rats bisphenol A: A narrative review of prenatal exposure effects on adipogenesis and childhood obesity via peroxisome proliferator-activated receptor gamma Association between urinary levels of bisphenol A and its monochlorinated derivative and obesity bisphenol A and diabetes, insulin resistance, cardiovascular disease and obesity: controversy in a (plastic) cup? bisphenol A and obesity in children and adolescents
ADROPIN is a novel regulator of endothelial function A novel peptide ADROPIN in cardiovascular diseases ADROPIN as a fat-burning hormone with multiple functions—Review of a decade of research Serum ADROPIN levels are decreased in patients with acute myocardial infarction ADROPIN deficiency is associated with increased adiposity and insulin resistance Three new players in energy regulation: preptin, ADROPIN and irisin Elevated plasma levels of ADROPIN in heart failure patients ADROPIN -physiological and pathophysiological role. Maternal and fetal ADROPIN levels in gestational diabetes mellitus Low serum ADROPIN is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients Regulation of substrate oxidation preferences in muscle by the peptide hormone ADROPIN Identification of ADROPIN as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism Therapeutic effects of ADROPIN on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance ADROPIN is associated with hyperhomocysteine and coronary atherosclerosis Deficiency of a new protein associated with cardiac syndrome X; called ADROPIN Inverse correlation between plasma ADROPIN and ET-1 levels in essential hypertension: A cross-sectional study Serum ADROPIN level in patients with stable coronary artery disease ADROPIN regulates cardiac energy metabolism and improves cardiac function and efficiency Serum ADROPIN levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index Low circulating ADROPIN concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans ADROPIN : An endocrine link between the biological clock and cholesterol homeostasis Association of serum ADROPIN concentrations with diabetic nephropathy Correlation of serum ADROPIN level with coronary artery disease A review of ADROPIN as the medium of dialogue between energy regulation and immune regulation Metabolic syndrome patients have lower levels of ADROPIN when compared with healthy overweight/obese and lean subjects Evaluation of the relationship between serum ADROPIN levels and blood pressure in obese children ADROPIN deficiency worsens HFD-induced metabolic defects ADROPIN correlates with aging-related neuropathology in humans and improves cognitive function in aging mice Serum ADROPIN levels are reduced in patients with inflammatory bowel diseases Circulating ADROPIN concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function Plasma ADROPIN levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus A novel biomarker in patients with knee osteoarthritis: ADROPIN Aerobic exercise training-induced changes in serum ADROPIN level are associated with reduced arterial stiffness in middle-aged and older adults ADROPIN : a hepatokine modulator of vascular function and cardiac fuel metabolism Investigation of ADROPIN and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease The effect of ADROPIN on lipid and glucose metabolism in rats with hyperlipidemia ADROPIN as a potential mediator of the metabolic system‐autonomic nervous system‐chronobiology axis: Implementing a personalized signature‐based platform for … Inverse association between carbohydrate consumption and plasma ADROPIN concentrations in humans Effects of ADROPIN on proliferation and differentiation of 3T3-L1 cells and rat primary preadipocytes Association between serum ADROPIN levels and gestational diabetes mellitus; a case–control study ADROPIN Serum Levels in Patients
An anxiolytic (/ˌæŋksiəˈlɪtɪk, ˌæŋksioʊ-/; also antipanic or antianxiety agent)[1] is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenicagents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms. The use of social interaction as a method for detecting ANXIOLYTIC activity of chlordiazepoxide-like drugs Thigmotaxis as a test for ANXIOLYTIC activity in rats Molecular basis of buspirone's ANXIOLYTIC action Use of the elevated plus maze in the search for novel ANXIOLYTIC agents The pet as an ANXIOLYTIC intervention. Preliminary report of a simple animal behavior model for the ANXIOLYTIC effects of benzodiazepines A sensitive open field measure of ANXIOLYTIC drug activity ANXIOLYTIC activity of an endogenous adrenal steroid Pharmacological and behavioral profile of alpidem as an ANXIOLYTIC ANXIOLYTIC and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat Conditioned defensive burying: a new paradigm for the study of ANXIOLYTIC agents A fully automated light/dark apparatus useful for comparing ANXIOLYTIC agents Future directions in ANXIOLYTIC pharmacotherapy The staircase test in mice: a simple and efficient procedure for primary screening of ANXIOLYTIC agents ANXIOLYTIC activity of Panax ginseng roots: an experimental study Animal models for predicting clinical efficacy of ANXIOLYTIC drugs: social behaviour One-trial tolerance to the ANXIOLYTIC effects of chlordiazepoxide in the plus-maze ANXIOLYTIC activity of adenosine receptor activation in mice. Chlordiazepoxide, an ANXIOLYTIC benzodiazepine, impairs place navigation in rats The potential ANXIOLYTIC activity of GR38032F, a 5-HT3-receptor antagonist. ANXIOLYTIC activity of Azadirachta indica leaf extract in rats. Characterisation of the phenomenon of “one-trial tolerance” to the ANXIOLYTIC effect of chlordiazepoxide in the elevated plus-maze The modified light/dark transition test in mice: evaluation of classic and putative ANXIOLYTIC and anxiogenic drugs. Baseline exploratory activity predicts ANXIOLYTIC responsiveness to diazepam in five mouse strains Chlordiazepoxide loses its ANXIOLYTIC action with long-term treatment ANXIOLYTIC effect of progesterone is associated with increases in cortical alloprenanolone and GABAA receptor function Further characterization of a simple, automated exploratory model for the ANXIOLYTIC effects of benzodiazepines Effects of ANXIOLYTIC and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice ANXIOLYTIC activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one Is tofisopam an atypical ANXIOLYTIC? Development of a class of selective cholecystokinin type B receptor antagonists having potent ANXIOLYTIC activity. Testing the abuse liability of ANXIOLYTIC and hypnotic drugs in humans Centrally administered neuropeptide Y (NPY) produces ANXIOLYTIC-like effects in animal anxiety models Possible ANXIOLYTIC effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea Distress vocalization in rat pups a simple screening method for ANXIOLYTIC drugs High doses of oxytocin cause sedation and low doses cause an ANXIOLYTIC-like effect in male rats Progesterone alters GABA and glutamate responsiveness: a possible mechanism for its ANXIOLYTIC action Comparison of alcohol-preferring (P) and nonpreferring (NP) rats on tests of anxiety and for the ANXIOLYTIC effects of ethanol Dehydroepiandrosterone is an ANXIOLYTIC in mice mice on the plus maze The central and basolateral
GUT –BRAIN AXIS Microbes and the GUT ‐BRAIN AXIS The microbiota-GUT -BRAIN AXIS GUT /BRAIN AXIS and the microbiota Is there a 'GUT –BRAIN –skin AXIS '? The role of GUT microbiota in the GUT -BRAIN AXIS : current challenges and perspectives GUT microbiota's effect on mental health: The GUT -BRAIN AXIS GUT -BRAIN psychology: rethinking psychology from the microbiota–GUT –BRAIN AXIS GUT –BRAIN AXIS : how the microbiome influences anxiety and depression Stress & the GUT -BRAIN AXIS : regulation by the microbiome The GUT -BRAIN AXIS : the missing link in depression The microbiome-GUT -BRAIN AXIS in health and disease The GUT -BRAIN AXIS , the human GUT microbiota and their integration in the development of obesity The microbiome‐GUT ‐BRAIN AXIS : from bowel to behavior GUT -BRAIN AXIS and behavior Microbiota and the GUT –BRAIN AXIS The GUT –BRAIN AXIS mediates sugar preference Microbial genes, BRAIN & behaviour–epigenetic regulation of the GUT –BRAIN AXIS The GUT –BRAIN AXIS : historical reflections Regulation of energy balance by a GUT –BRAIN AXIS and involvement of the GUT microbiota Psychobiotics and the GUT –BRAIN AXIS : in the pursuit of happiness The GUT –BRAIN AXIS and the microbiome: mechanisms and clinical implications The microbiota–GUT –BRAIN AXIS in obesity The GUT –BRAIN AXIS in obesity The microbiome-GUT -BRAIN AXIS in acute and chronic BRAIN diseases Mind-altering with the GUT : Modulation of the GUT -BRAIN AXIS with probiotics GUT microbiota, the immune system, and diet influence the neonatal GUT –BRAIN AXIS Tryptophan Metabolism by GUT Microbiome and GUT -BRAIN -AXIS : An in silico Analysis Schizophrenia and the GUT –BRAIN AXIS Impact of microbiota on central nervous system and neurological diseases: the GUT -BRAIN AXIS Microbiota-GUT -BRAIN AXIS : new therapeutic opportunities Pathogenesis of Parkinson disease—the GUT –BRAIN AXIS and environmental factors Neuropeptides and the microbiota-GUT -BRAIN AXIS Microbiota-GUT -BRAIN AXIS and the central nervous system Microbiota regulation of the mammalian GUT –BRAIN AXIS The role of the GUT /BRAIN AXIS in modulating food intake The neuroendocrinology of the microbiota-GUT -BRAIN AXIS : a behavioural perspective Recognizing depression from the microbiota–GUT –BRAIN AXIS Interplay between the GUT -BRAIN AXIS , obesity and cognitive function GUT –BRAIN AXIS : regulation of glucose metabolism The role of nutrition and the GUT -BRAIN AXIS in psychiatry: a review of the literature Oxidative stress and the microbiota-GUT -BRAIN AXIS Microbiota-GUT -BRAIN AXIS and cognitive function The vagus nerve at the interface of the microbiota-GUT -BRAIN AXIS GUT –BRAIN AXIS and mood disorder The regulation of food intake by the GUT -BRAIN AXIS : implications for obesity Exercise influence on the microbiome–GUT –BRAIN AXIS Food for thought: The role of nutrition in the microbiota-GUT –BRAIN AXIS Neurotransmitters: The critical modulators regulating GUT –BRAIN AXIS The GUT –BRAIN AXIS , paving the way to BRAIN cancer The microbiota-immune AXIS as a central mediator of GUT -BRAIN communication The GUT -BRAIN AXIS : interactions between enteric microbiota, central and enteric nervous systems Autism and nutrition: the role of
The role of CDK5 /P25 formation/inhibition in neurodegeneration. A decade of CDK5 CDK5 deregulation in the pathogenesis of Alzheimer's disease Conversion of p35 to p25 deregulates CDK5 activity and promotes neurodegeneration The CDK5 /p35 kinase is essential for neurite outgrowth during neuronal differentiation. The p35/CDK5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity CDK5 -mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis p35, the neuronal-specific activator of cyclin-dependent kinase 5 (CDK5 ) is degraded by the ubiquitin-proteasome pathway Cables links CDK5 and c-Abl and facilitates CDK5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth Aberrant CDK5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by CDK5 CDK5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism Effects of chronic exposure to cocaine are regulated by the neuronal protein CDK5 Phosphorylation of DARPP-32 by CDK5 modulates dopamine signalling in neurons CDK5 serves as a major control point in neurotransmitter release Mice lacking p35, a neuronal specific activator of CDK5 , display cortical lamination defects, seizures, and adult lethality Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5 /P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer's Disease: A … Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin‐dependent kinases cdc2, cdk2 and CDK5 Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and CDK5 CDK5 is a key factor in tau aggregation and tangle formation in vivo Fyn and CDK5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex Semaphorin3A signalling is mediated via sequential CDK5 and GSK3β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying … Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of CDK5 Structure and regulation of the CDK5 -p25nck5a complex Deregulation of CDK5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions CDK5 /p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity Inhibition of tau phosphorylating protein kinase CDK5 prevents β-amyloid-induced neuronal death A Jekyll and Hyde kinase: roles for CDK5 in brain development and disease An isoform of the neuronal cyclin-dependent kinase 5 (CDK5 ) activator Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice NUDEL is a novel CDK5 substrate that associates with LIS1 and cytoplasmic dynein … specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5 … Accumulation of cyclin-dependent kinase 5 (CDK5 ) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration CDK5 is essential for synaptic vesicle endocytosis CDK5 : a multifaceted kinase in neurodegenerative diseases CDK5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors CDK5 phosphorylation of doublecortin ser297 regulates its effect on neuronal migration The protein kinase CDK5 : structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology S-Nitrosylation activates CDK5 and contributes to synaptic spine loss induced by
Potential use of POLYPHENOLS in the battle against COVID-19 Phytochemicals containing biologically active POLYPHENOLS as an effective agent against COVID-19-inducing coronavirus POLYPHENOLS are potential nutritional adjuvants for targeting COVID‐19 A comprehensive review of the potential use of green tea POLYPHENOLS in the management of COVID-19 Antiviral activity of green tea and black tea POLYPHENOLS in prophylaxis and treatment of COVID-19: A review Can natural POLYPHENOLS help in reducing cytokine storm in COVID-19 patients? POLYPHENOLS as alternative treatments of COVID-19 Cell clearing systems as targets of POLYPHENOLS in viral infections: Potential implications for COVID-19 pathogenesis The impact of POLYPHENOLS -based diet on the inflammatory profile in COVID-19 elderly and obese patients Can phytotherapy with POLYPHENOLS serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)? Tea POLYPHENOLS Prevent and Intervene in COVID-19 through Intestinal Microbiota Natural POLYPHENOLS as immunomodulators to rescue immune response homeostasis: Quercetin as a research model against severe COVID-19 Exploitation of POLYPHENOLS and proteins using nanoencapsulation for anti-viral and brain boosting properties–Evoking a synergistic strategy to combat COVID-19 … Battle against Coronavirus: Repurposing old friends (Food borne POLYPHENOLS ) for new enemy (COVID-19) An In-silico investigation of potential natural POLYPHENOLS for the targeting of COVID main protease inhibitor Identification of potent COVID-19 main protease (Mpro) inhibitors from natural POLYPHENOLS : an in silico strategy unveils a hope against CORONA The impact of curcumin derived POLYPHENOLS on the structure and flexibility COVID-19 main protease binding pocket: A molecular dynamics simulation study Potential Application of Tea POLYPHENOLS to the Prevention of COVID-19 Infection: Based on the Gut-Lung Axis POLYPHENOLS &ots=u3PbOS8Qzs&sig=om9uOs39ZZ4LQznbx2vjBpJO-zw">The potential health of POLYPHENOLS during the pandemic of COVID-19 Beneficial effect of POLYPHENOLS in COVID‐19 and the ectopic F1FO‐ATP synthase: Is there a link? Multidimensional in silico strategy for identification of natural POLYPHENOLS -based SARS-CoV-2 main protease (Mpro) inhibitors to unveil a hope against COVID-19 Can POLYPHENOLS be Used as Anti-Inflammatory Agents against COVID-19 (SARS-CoV-2)-Induced Inflammation? A perspective on the use of POLYPHENOLS nano-formulation as a nutritional strategy to manage the symptoms of the infected patient with COVID-19 Possible health benefits of POLYPHENOLS in neurological disorders associated with COVID-19 Potential of the triad of fatty acids, POLYPHENOLS , and prebiotics from cucurbita against COVID-19 in diabetic patients: A review … Insights into Potential Beneficial Effects of Bioactive Compounds of Bee Products in Boosting Immunity to Fight COVID-19 Pandemic: Focus on Zinc and POLYPHENOLS Exploration of plant-derived natural POLYPHENOLS toward COVID-19 main protease inhibitors: DFT, molecular docking approach, and molecular dynamics … Chemical profiling of POLYPHENOLS in Thunbergia alata and in silico virtual screening of their antiviral activities against COVID-19 A Comprehensive Review of the Potential Use of Green Tea POLYPHENOLS in the Management of COVID-19 Flavonoids are promising safe therapy against COVID-19 Flavonoids: A complementary approach to conventional therapy of COVID-19? New perspectives on natural flavonoids on COVID‐19‐induced lung injuries Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease A drug repurposing approach towards elucidating the potential
Oxidative stress, toxicology, and pharmacology of CYP2E1 Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity CYP2E1 and oxidative liver injury by alcohol Human CYP2E1 is regulated by miR-378 Role of CYP2E1 in the Hepatotoxicity of Acetaminophen (∗) CYP2E1 CYP2E1: from ash to nash Human hepatic CYP2E1 expression during development Ethanol Induces CYP2E1 by Protein Stabilization: ROLE OF UBIQUITIN CONJUGATION IN THE RAPID DEGRADATION OF CYP2E1 (∗) Role of CYP2E1 in Diethylnitrosamine-Induced Hepatocarcinogenesis In vivo CYP2E1-dependent toxicity and oxidative stress in HepG2 cells Different regulation and expression of the human CYP2E1 gene due to the Rsal polymorphism in the 5'-flanking region Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression The CYP2E1-humanized transgenic mouse: role of CYP2E1 in acetaminophen hepatotoxicity Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1 Genetic polymorphism of human CYP2E1: characterization of two variant alleles Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan CYP2E1 and risk of chemically mediated cancers Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1 Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression CYP2E1 mediated isoniazid-induced hepatotoxicity in rats Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. CYP2E1 is not involved in early alcohol-induced liver injury Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone CYP2E1—biochemical and toxicological aspects and role in alcohol-induced liver injury CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease Developmental Expression of CYP2E1 in the Human Liver: Hypermethylation Control of Gene Expression During the Neonatal Period Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity The alcohol-inducible form of cytochrome P450 (CYP2E1): role in toxicology and regulation of expression Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1 Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling Induction of CYP2E1 in liver, kidney, brain and intestine during chronic ethanol administration and withdrawal: evidence that CYP2E1 possesses a rapid phase half … Development and properties of HepG2 cells that constitutively express CYP2E1 Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis Human CYP2E1
DEPERSONALIZATION: neurobiological perspectives On DEPERSONALIZATION. DEPERSONALIZATION DEPERSONALIZATION disorder: thinking without feeling DEPERSONALIZATION: a selective impairment of self-awareness Autonomic response in DEPERSONALIZATION disorder DEPERSONALIZATION in response to life-threatening danger Unpacking the DEPERSONALIZATION syndrome: an exploratory factor analysis on the Cambridge DEPERSONALIZATION Scale DEPERSONALIZATION disorder: pharmacological approaches Analysis of a schizophrenic state with DEPERSONALIZATION Feeling unreal: a DEPERSONALIZATION disorder update of 117 cases The role of childhood interpersonal trauma in DEPERSONALIZATION disorder DEPERSONALIZATION: A new look at a neglected syndrome Feeling unreal: DEPERSONALIZATION disorder and the loss of the self DEPERSONALIZATION: A valid dimension of burnout? The phenomenological stability of DEPERSONALIZATION: comparing the old with the new Feeling unreal: a PET study of DEPERSONALIZATION disorder DEPERSONALIZATION: I. Aetiology and phenomenology Feeling unreal: Cognitive processes in DEPERSONALIZATION DEPERSONALIZATION in the face of life-threatening danger: A description In-group identification as a function of DEPERSONALIZATION, distinctiveness, and status DEPERSONALIZATION phenomena in a sample population of college students The DEPERSONALIZATION of retailing: Its impact on the'lone The Phobic Anxiety-DEPERSONALIZATION Syndrome [Abridged] DEPERSONALIZATION: a conceptual history Social categorization, DEPERSONALIZATION, and group behavior DEPERSONALIZATION in accident victims and psychiatric patients. Gender-role differences, work stress and DEPERSONALIZATION The detection and measurement of DEPERSONALIZATION disorder DEPERSONALIZATION phenomena in psychiatric patients Koro—a culture-bound DEPERSONALIZATION syndrome Review of the relationship between obsession and DEPERSONALIZATION Cognitive functioning in DEPERSONALIZATION disorder Self-induced DEPERSONALIZATION syndrome. A case series of 223 patients with DEPERSONALIZATION-derealization syndrome DEPERSONALIZATION of business in ancient Rome Intergroup differentiation in computer-mediated communication: Effects of DEPERSONALIZATION. The spectrum of organic DEPERSONALIZATION: a review plus four new cases DEPERSONALIZATION: Standing in the spaces between recognition and interpellation A study of DEPERSONALIZATION in students Objectification leads to DEPERSONALIZATION: The denial of mind and moral concern to objectified others DEPERSONALIZATION in the face of life-threatening danger: An interpretation De-constructing DEPERSONALIZATION: further evidence for symptom clusters DEPERSONALIZATION disorder and anxiety: a special relationship? Treatment of DEPERSONALIZATION disorder with clomipramine Single item measures of emotional exhaustion and DEPERSONALIZATION are useful for assessing burnout in medical professionals DEPERSONALIZATION in panic disorder: a clinical study Normal and abnormal DEPERSONALIZATION Prevalence of DEPERSONALIZATION and derealization experiences in a rural population Emotion and the unreal self: DEPERSONALIZATION disorder and de-affectualization Outcomes and antecedents of teacher DEPERSONALIZATION: The role of intrinsic orientation for teaching. DEPERSONALIZATION, mindfulness, and childhood trauma The role of anxiety in DEPERSONALIZATION Concurrent validity of single-item measures of emotional exhaustion and DEPERSONALIZATION in burnout assessment The DEPERSONALIZATION of patients: A profile gleaned from narratives When and how does DEPERSONALIZATION increase conformity to group norms in computer-mediated communication? Teacher burnout: A quantitative analysis of emotional exhaustion, personal accomplishment, and DEPERSONALIZATION Feelings of unreality: A conceptual and phenomenological analysis of the language of DEPERSONALIZATION The effects of DEPERSONALIZATION and organizational cynicism levels on the job satisfaction of educational inspectors Regional cerebral blood flow and DEPERSONALIZATION after tetrahydrocannabinol administration. DEPERSONALIZATION disorder: a functional neuroanatomical perspective Fair trade and the DEPERSONALIZATION of ethics Prevalence, correlates, and predictors of DEPERSONALIZATION experiences in the German general population Bodily feeling in DEPERSONALIZATION: A phenomenological account Effect of
HAIR REPIGMENTATION during immunotherapy treatment with an anti–programmed cell death 1 and anti–programmed cell death ligand 1 agent for lung cancer Medication-induced REPIGMENTATION of gray HAIR: a systematic review Erlotinib-induced HAIR REPIGMENTATION Spontaneous HAIR REPIGMENTATION in an 80-year-old man: a case of melanoma-associated HAIR REPIGMENTATION and review of the literature HAIR REPIGMENTATION in melanoma HAIR REPIGMENTATION associated with the use of lenalidomide: graying may not be an irreversible process! HAIR REPIGMENTATION in lentigo maligna Localized HAIR REPIGMENTATION in a 91-year-old woman HAIR REPIGMENTATION associated with the use of brentuximab REPIGMENTATION of HAIR following adalimumab therapy Localized gray HAIR REPIGMENTATION (canities reversal) in patients with frontal fibrosing alopecia. HAIR REPIGMENTATION associated with thalidomide use for the treatment of multiple myeloma Desmoplastic melanoma presenting with localized HAIR REPIGMENTATION REPIGMENTATION and curling of HAIR after acitretin therapy Long‐term HAIR REPIGMENTATION following a HAIR transplant for frontal scarring alopecia HAIR REPIGMENTATION With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis HAIR REPIGMENTATION With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis Permanent localized HAIR REPIGMENTATION following herpes zoster infection REPIGMENTATION of HAIR associated with melanoma in situ of scalp HAIR REPIGMENTATION After Mohs Micrographic Surgery and Secondary Intention Wound Healing on the Scalp of an 84-Year-Old Woman HAIR REPIGMENTATION With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis—Reply HAIR REPIGMENTATION: case report HAIR REPIGMENTATION in an elderly patient: case report HAIR REPIGMENTATION in an elderly patient: case report The First Case of Ustekinumab-Associated HAIR REPIGMENTATION and a Proposed Mechanism of Action HAIR REPIGMENTATION and curling: case report Atezolizumab/nivolumab/pembrolizumab: HAIR REPIGMENTATION: 14 case reports Global REPIGMENTATION Strategy of Grey HAIR Follicles by Targeting Oxidative Stress and Stem Cells Protection REPIGMENTATION of gray HAIR in lesions of annular elastolytic giant cell granuloma Novel technique for REPIGMENTATION of senescence grey HAIR Comparison of efficacy of noncultured HAIR follicle cell suspension and noncultured epidermal cell suspension in REPIGMENTATION of leukotrichia and skin patch in …
Supraspinal contributions to HYPERALGESIA Neurotrophins and HYPERALGESIA Basic and clinical aspects of visceral HYPERALGESIA Neurocircuitry of illness-induced HYPERALGESIA Neurogenic HYPERALGESIA: psychophysical studies of underlying mechanisms Peripheral and central mechanisms of cutaneous HYPERALGESIA Experimental evidence on the nature of cutaneous HYPERALGESIA Multiple mechanisms of secondary HYPERALGESIA Peripheral and central mechanisms of NGF‐induced HYPERALGESIA Characterization of cytokine-induced HYPERALGESIA Inflammatory models of pain and HYPERALGESIA The pivotal role of tumour necrosis factor alpha in the development of inflammatory HYPERALGESIA. Kinins and their receptors in HYPERALGESIA Different patterns of HYPERALGESIA induced by experimental inflammation in human skin Mechanisms of tumor necrosis factor-α (TNF-α) HYPERALGESIA Involvement of nitric oxide in spinally mediated HYPERALGESIA in the mouse A new and sensitive method for measuring thermal nociception in cutaneous HYPERALGESIA Nerve growth factor-induced HYPERALGESIA in the neonatal and adult rat Dynamic and static components of mechanical HYPERALGESIA in human hairy skin Central changes in processing of mechanoreceptive input in capsaicin‐induced secondary HYPERALGESIA in humans. A new animal model for assessing mechanisms and management of muscle HYPERALGESIA Primary and secondary HYPERALGESIA in a rat model for human postoperative pain Topical application of clonidine relieves HYPERALGESIA in patients with sympathetically maintained pain HYPERALGESIA in experimental neuropathy is dependent on the TNF receptor 1 Cytokines, nerve growth factor and inflammatory HYPERALGESIA: the contribution of tumour necrosis factor α The role of the polymorphonuclear leukocyte in HYPERALGESIA A pharmacologic analysis of mechanical HYPERALGESIA in streptozotocin/diabetic rats HYPERALGESIA due to nerve injury: role of neutrophils Effects of antihyperalgesic drugs on experimentally induced HYPERALGESIA in man A peripheral sympathetic component in inflammatory HYPERALGESIA Neurogenic HYPERALGESIA: the search for the primary cutaneous afferent fibers that contribute to capsaicin-induced pain and HYPERALGESIA I-Prostaglandin HYPERALGESIA, a cAMP/Ca2+ dependent process Neurogenic HYPERALGESIA: central neural correlates in responses of spinothalamic tract neurons Low‐dose lidocaine reduces secondary HYPERALGESIA by a central mode of action Contribution of interleukin‐1β to the inflammation‐induced increase in nerve growth factor levels and inflammatory HYPERALGESIA Myelinated afferents signal the HYPERALGESIA associated with nerve injury Evidence for different mechanisms of primary and secondary HYPERALGESIA following heat injury to the glabrous skin HYPERALGESIA due to nerve damage: role of nerve growth factor Patterns of HYPERALGESIA in complex regional pain syndrome Cytokine-mediated inflammatory HYPERALGESIA limited by interleukin-10. Nitric oxide mediates the thermal HYPERALGESIA produced in a model of neuropathic pain in the rat Leukotriene B4 Produces HYPERALGESIA That Is Dependent on Polymorphonuclear Leukocytes Pain and HYPERALGESIA in osteoarthritis of the hands Mediation of primary afferent peripheral HYPERALGESIA by the cAMP second messenger system The possible role of glia in nociceptive processing and HYPERALGESIA in the spinal cord of the rat Peripheral neural mechanisms of cutaneous HYPERALGESIA following mild injury by heat Direct cutaneous HYPERALGESIA induced by adenosine Nociceptor modulated central sensitization causes mechanical HYPERALGESIA in acute chemogenic and chronic neuropathic pain Cutaneous HYPERALGESIA induced by peripheral injection of interleukin-1β in the rat Dose-dependent pain and mechanical HYPERALGESIA in humans after intradermal injection of capsaicin Bradykinin initiates cytokine-mediated inflammatory HYPERALGESIA. Long-lasting HYPERALGESIA induced by fentanyl in rats: preventive effect